Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 19Paclitaxel 10Carboplatin 10Magnetic Resonance Spectroscopy 9Docetaxel 9Cyclophosphamide 9Specimen Handling 8Cisplatin 8Gemcitabine 7Drug Therapy 7sargramostim 6Pemetrexed 6Nivolumab 6fludarabine 5aldesleukin 5Trastuzumab 5Bevacizumab 5Taxes 4Fluorouracil 4Blood Specimen Collection 4Amifostine 4veliparib 3pegfilgrastim 3Topotecan 3Irinotecan 3IFL protocol 3Fluorodeoxyglucose F18 3Etoposide 3Early Intervention, Educational 3tariquidar 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × vofatamab × Gynecologic × Clear all
NCT05363605 2023-12-19

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Fusion Pharmaceuticals Inc.

Phase 1/2 Terminated
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Liver Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡